19-398 - An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSDStatus: open
A Phase 3, External Placebo-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
This is a phase 3 efficacy and safety study of Ravulizumab in adults with neuromyelitis optica spectrum disorder (NMOSD). The goal is to provide NMOSD patients another treatment option for their condition that reduces treatment burden while maintaining a comparable risk/benefit profile.